Frequence, Spectrum and Prognostic Impact of Additional Malignancies in Patients With Gastrointestinal Stromal Tumors
Currently available data on prognostic implication of additional neoplasms in GIST miss comprehensive information on patient outcome with regard to overall or disease specific and disease free survival. Registry data of GIST patients with and without additional neoplasm were compared in retrospectiv...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2015-01-01
|
| Series: | Neoplasia: An International Journal for Oncology Research |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558614001912 |
| _version_ | 1811297482812948480 |
|---|---|
| author | K. Kramer S. Wolf B. Mayer S.A. Schmidt A. Agaimy D. Henne-Bruns U. Knippschild M. Schwab M. Schmieder |
| author_facet | K. Kramer S. Wolf B. Mayer S.A. Schmidt A. Agaimy D. Henne-Bruns U. Knippschild M. Schwab M. Schmieder |
| author_sort | K. Kramer |
| collection | DOAJ |
| description | Currently available data on prognostic implication of additional neoplasms in GIST miss comprehensive information on patient outcome with regard to overall or disease specific and disease free survival. Registry data of GIST patients with and without additional neoplasm were compared in retrospective case series. We investigated a total of 836 patients from the multi-center Ulmer GIST registry. Additionally, a second cohort encompassing 143 consecutively recruited patients of a single oncology center were analyzed. The frequency of additional malignant neoplasms in GIST patients was 31.9% and 42.0% in both cohorts with a mean follow-up time of 54 and 65 months (median 48 and 60 months), respectively. The spectrum of additional neoplasms in both cohorts encompasses gastrointestinal tumors (43.5%), uro-genital and breast cancers (34.1%), hematological malignancies (7.3%), skin cancer (7.3%) and others. Additional neoplasms have had a significant impact on patient outcome. The five year overall survival in GIST with additional malignant neoplasms (n = 267) was 62.8% compared to 83.4% in patients without other tumors (n = 569) (P < .001, HR=0.397, 95% CI: 0.298-0.530). Five-year disease specific survival was not different between both groups (90.8% versus 90.9%). 34.2% of all deaths (n = 66 of n = 193) were GIST-related. The presented data suggest a close association between the duration of follow-up and the rate of additional malignancies in GIST patients. Moreover the data indicate a strong impact of additional malignant neoplasms in GIST on patient outcome. A comprehensive follow-up strategy of GIST patients appears to be warranted. |
| first_indexed | 2024-04-13T06:04:54Z |
| format | Article |
| id | doaj.art-37246360b7e2478984374a1154f0232c |
| institution | Directory Open Access Journal |
| issn | 1476-5586 1522-8002 |
| language | English |
| last_indexed | 2024-04-13T06:04:54Z |
| publishDate | 2015-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neoplasia: An International Journal for Oncology Research |
| spelling | doaj.art-37246360b7e2478984374a1154f0232c2022-12-22T02:59:17ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022015-01-0117113414010.1016/j.neo.2014.12.001Frequence, Spectrum and Prognostic Impact of Additional Malignancies in Patients With Gastrointestinal Stromal TumorsK. Kramer0S. Wolf1B. Mayer2S.A. Schmidt3A. Agaimy4D. Henne-Bruns5U. Knippschild6M. Schwab7M. Schmieder8Department of General and Visceral Surgery, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm GermanyDepartment of Surgery, District-Hospital St. Gallen, Rorschacher Strasse 95, 9007 St.Gallen, SwitzerlandInstitute of Epidemiology and Medical Biometry, Schwabstr. 13, University of Ulm, 89075 Ulm, GermanyDepartment of Diagnostic and Interventional Radiology, University of Ulm, Albert-Einstein-Allee 23, 89081 Ulm, GermanyInstitute of Pathology, University of Erlangen, Krankenhausstr. 8–10, 91054 Erlangen GermanyDepartment of General and Visceral Surgery, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm GermanyDepartment of General and Visceral Surgery, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm GermanyDr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstraße 112, 70376 Stuttgart, GermanyDepartment of Internal Medicine, Alb-Fils-Kliniken, Eichertstr. 3, 73035 Goeppingen, GermanyCurrently available data on prognostic implication of additional neoplasms in GIST miss comprehensive information on patient outcome with regard to overall or disease specific and disease free survival. Registry data of GIST patients with and without additional neoplasm were compared in retrospective case series. We investigated a total of 836 patients from the multi-center Ulmer GIST registry. Additionally, a second cohort encompassing 143 consecutively recruited patients of a single oncology center were analyzed. The frequency of additional malignant neoplasms in GIST patients was 31.9% and 42.0% in both cohorts with a mean follow-up time of 54 and 65 months (median 48 and 60 months), respectively. The spectrum of additional neoplasms in both cohorts encompasses gastrointestinal tumors (43.5%), uro-genital and breast cancers (34.1%), hematological malignancies (7.3%), skin cancer (7.3%) and others. Additional neoplasms have had a significant impact on patient outcome. The five year overall survival in GIST with additional malignant neoplasms (n = 267) was 62.8% compared to 83.4% in patients without other tumors (n = 569) (P < .001, HR=0.397, 95% CI: 0.298-0.530). Five-year disease specific survival was not different between both groups (90.8% versus 90.9%). 34.2% of all deaths (n = 66 of n = 193) were GIST-related. The presented data suggest a close association between the duration of follow-up and the rate of additional malignancies in GIST patients. Moreover the data indicate a strong impact of additional malignant neoplasms in GIST on patient outcome. A comprehensive follow-up strategy of GIST patients appears to be warranted.http://www.sciencedirect.com/science/article/pii/S1476558614001912 |
| spellingShingle | K. Kramer S. Wolf B. Mayer S.A. Schmidt A. Agaimy D. Henne-Bruns U. Knippschild M. Schwab M. Schmieder Frequence, Spectrum and Prognostic Impact of Additional Malignancies in Patients With Gastrointestinal Stromal Tumors Neoplasia: An International Journal for Oncology Research |
| title | Frequence, Spectrum and Prognostic Impact of Additional Malignancies in Patients With Gastrointestinal Stromal Tumors |
| title_full | Frequence, Spectrum and Prognostic Impact of Additional Malignancies in Patients With Gastrointestinal Stromal Tumors |
| title_fullStr | Frequence, Spectrum and Prognostic Impact of Additional Malignancies in Patients With Gastrointestinal Stromal Tumors |
| title_full_unstemmed | Frequence, Spectrum and Prognostic Impact of Additional Malignancies in Patients With Gastrointestinal Stromal Tumors |
| title_short | Frequence, Spectrum and Prognostic Impact of Additional Malignancies in Patients With Gastrointestinal Stromal Tumors |
| title_sort | frequence spectrum and prognostic impact of additional malignancies in patients with gastrointestinal stromal tumors |
| url | http://www.sciencedirect.com/science/article/pii/S1476558614001912 |
| work_keys_str_mv | AT kkramer frequencespectrumandprognosticimpactofadditionalmalignanciesinpatientswithgastrointestinalstromaltumors AT swolf frequencespectrumandprognosticimpactofadditionalmalignanciesinpatientswithgastrointestinalstromaltumors AT bmayer frequencespectrumandprognosticimpactofadditionalmalignanciesinpatientswithgastrointestinalstromaltumors AT saschmidt frequencespectrumandprognosticimpactofadditionalmalignanciesinpatientswithgastrointestinalstromaltumors AT aagaimy frequencespectrumandprognosticimpactofadditionalmalignanciesinpatientswithgastrointestinalstromaltumors AT dhennebruns frequencespectrumandprognosticimpactofadditionalmalignanciesinpatientswithgastrointestinalstromaltumors AT uknippschild frequencespectrumandprognosticimpactofadditionalmalignanciesinpatientswithgastrointestinalstromaltumors AT mschwab frequencespectrumandprognosticimpactofadditionalmalignanciesinpatientswithgastrointestinalstromaltumors AT mschmieder frequencespectrumandprognosticimpactofadditionalmalignanciesinpatientswithgastrointestinalstromaltumors |